Adaptimmune Therapeutics PLC
NASDAQ:ADAP
Adaptimmune Therapeutics PLC
Interest Income Expense
Adaptimmune Therapeutics PLC
Interest Income Expense Peer Comparison
Competitive Interest Income Expense Analysis
Latest Figures & CAGR of Competitors
Company | Interest Income Expense | CAGR 3Y | CAGR 5Y | CAGR 10Y | |
---|---|---|---|---|---|
Adaptimmune Therapeutics PLC
NASDAQ:ADAP
|
Interest Income Expense
$6m
|
CAGR 3-Years
35%
|
CAGR 5-Years
73%
|
CAGR 10-Years
N/A
|
|
Centessa Pharmaceuticals PLC
NASDAQ:CNTA
|
Interest Income Expense
$570k
|
CAGR 3-Years
N/A
|
CAGR 5-Years
N/A
|
CAGR 10-Years
N/A
|
|
Autolus Therapeutics PLC
NASDAQ:AUTL
|
Interest Income Expense
-$29m
|
CAGR 3-Years
N/A
|
CAGR 5-Years
N/A
|
CAGR 10-Years
N/A
|
|
Bicycle Therapeutics PLC
NASDAQ:BCYC
|
Interest Income Expense
$13.4m
|
CAGR 3-Years
N/A
|
CAGR 5-Years
126%
|
CAGR 10-Years
N/A
|
|
Immunocore Holdings PLC
NASDAQ:IMCR
|
Interest Income Expense
-£344k
|
CAGR 3-Years
21%
|
CAGR 5-Years
N/A
|
CAGR 10-Years
N/A
|
|
Genus PLC
LSE:GNS
|
Interest Income Expense
-£10.1m
|
CAGR 3-Years
N/A
|
CAGR 5-Years
-102%
|
CAGR 10-Years
-20%
|
See Also
What is Adaptimmune Therapeutics PLC's Interest Income Expense?
Interest Income Expense
6m
USD
Based on the financial report for Dec 31, 2023, Adaptimmune Therapeutics PLC's Interest Income Expense amounts to 6m USD.
What is Adaptimmune Therapeutics PLC's Interest Income Expense growth rate?
Interest Income Expense CAGR 5Y
73%
Over the last year, the Interest Income Expense growth was 287%. The average annual Interest Income Expense growth rates for Adaptimmune Therapeutics PLC have been 35% over the past three years , 73% over the past five years .